Abstract: The present invention relates to a method of diagnosing depression in a subject. Specifically, the present invention relates to diagnosing depression in a subject by providing a sample of the microbiome from the subject; determining the quantitative level or presence of one or more bacterial species in the sample; and diagnosing depression based on the quantitative level or presence of the one or more bacterial species in the sample.

Abstract: The present invention relates to a method of predicting response to treatment with a disease-modifying anti-rheumatic drug, and/or classifying disease activity in a subject with rheumatoid arthritis by determining the quantitative level of one or more biomarkers and either predicting response to treatment with a disease-modifying anti-rheumatic drug, classifying disease activity, and/el or predicting response to treatment with a disease-modifying anti-rheumatic drug and classifying disease activity.

Abstract: This invention relates to predicting a subjects responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in the subject.